Vir Biotechnology reported a significant increase in cash reserves to approximately $1.01 billion in Q2 2026, thanks to a strategic collaboration with Astellas, which included a $240 million upfront payment. The partnership focuses on VIR-5500, a treatment for prostate cancer, with early-stage trials expanding into multiple cohorts. Vir’s Q2 revenue rose to $238.9 million, marking a recovery from a previous loss, while R&D expenses increased due to milestone payments and preparations for commercializing a chronic hepatitis delta program. The company is also advancing in this field, with the ECLIPSE Phase 3 trials fully enrolled and data expected by early 2027.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/vir-biotechnology-astellas-deal-pushes-cash-above-1-billion-and-extends-runway-into-second-half-of-2028/
